Adage Capital Partners
TBPH icon

Adage Capital Partners’s Theravance Biopharma TBPH Stock Holding History

Adage Capital Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-700,000
Closed -$10.3M – 880
2020
Q3 		$10.3M Sell
700,000
-275,000
-28% -$5.15M 0.03% 515
2020
Q2 		$20.5M Buy
975,000
+200,000
+26% +$5.14M 0.05% 380
2020
Q1 		$17.9M Buy
+775,000
New +$19.4M 0.05% 345

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners's TBPH Position: Q4 2020 in Review

Adage Capital Partners sold out of Theravance Biopharma (TBPH) in Q4 2020, closing a stake of 700,000 shares — an estimated $10.3M sold.

Adage Capital Partners first reported a position in TBPH in Q1 2020 and held it in 3 quarters. The position peaked at $20.5M in Q2 2020. 107 funds tracked by Wall St. Rank hold TBPH as of Q4 2020.

  • Adage Capital Partners reported no remaining Theravance Biopharma position as of Q4 2020 after selling out during the quarter.
  • Adage Capital Partners sold 700,000 Theravance Biopharma shares in Q4 2020, an estimated $10.3M.
  • Adage Capital Partners first reported a position in Theravance Biopharma in Q1 2020 and held it in 3 quarters.
  • Adage Capital Partners's Theravance Biopharma position peaked at $20.5M in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2020.

Based on Adage Capital Partners's 13F filing for Q4 2020, filed 16 Feb 2021.